Company intelligence / Profile preview
Rapid Dose Therapeutics
- Ownership
- Private
- Development stage
- Other
Overview
Rapid Dose Therapeutics has commercialized its proprietary QuickStrip™ oral thin film technology with several over-the-counter and dental products already available. The company’s clinical-stage work includes a Health Canada-approved trial evaluating cannabinoid-infused QuickStrips for pain management and neuroprotection in sports concussions. The company also partners with compounding labs to expand prescription pharmaceutical applications of its technology.
- Therapeutic areas
- NeurologyPsychiatryHematologyEndocrinologyOther
- Modalities
- DeviceSmall moleculeBiologicVaccineNutraceuticalsCannabis-derived compounds
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Rapid Dose Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rapid Dose Therapeutics.